Friday, 03 Apr 2020

You are here

Overmedication of America

Recent research from the Lown Institute reports that 750 older Americans are hospitalized daily because of serious side effects from and the core problem is that of polypharmacy, especially in the elderly. 

Polypharmacy is a grown problem. With the addition of each new medication, the odds of a serious adverse event increases 7 to 10 percent with each drug. Today more than 40 percent of older Americans regularly take 5 or more medications and nearly 20 percent take more than 10 drugs.  This does not even include over-the-counter medications, which if included, would hve two-thirds of older adults taking 5 or more medications daily.

Americans take an average of 12 different medications yearly, many of which could also be addressed with diet and lifestyle changes. Since the 1970, prescription drug spending has almost doubled, accounting for 10 cents out of every health care dollar. Current spending on prescription medications in the U.S. is as much as $400 billion per year.

The Lown Institute predicts, over the next decade there will be more than 4.5 million hospitalizations of older adults for serious side effects of medications.  To deal with this issue they have released the results of a multidisciplinary expert panel aimed at reducing inappropriate or unnecessary medications could save as much as $62 billion over the next decade in unnecessary hospitalization for older adults alone.

Their paper "Eliminating Medication Overload: A National Action Plan", provides recommendations for policymakers, foundations, health care institutions, clinicians, and patients across five key categories:

  1. Implement “prescription checkups,” medication reviews that give patients and clinicians opportunities to deprescribe (discontinue or reduce doses) appropriately.
  2. Raise awareness among patients, clinicians, and the general public about the potential harms of multiple medication use.
  3. Improve information at the point of care to ensure clinicians know exactly which medications their patients are taking, and to give clinicians accurate information about the harms and benefits of medications.
  4. Educate and train health professionals to reduce medication overload, by incorporating information on geriatric care and deprescribing training into professional schools and continuing education.
  5. Reduce pharmaceutical industry influence by limiting pharma sales rep visits to clinicians and direct-to-consumer advertising.

 

Add new comment

More Like This

Rheumatic Disease Drugs and COVID-19

We are in the early stages of trying to limit the morbid and mortal consequences of the corona virus pandemic of 2020. Not surprisingly, the recommendations designed to limit exposure and damage continually highlight the fact that the elderly and immunosuppressed may be amongst the most severely affected should they become infected with this virus. This has led to a great deal of uncertainty by patients and providers about how rheumatic diseases and their treatments need to be specifically addressed.

EMA Final Recommendations on VTE Risk with Tofacitinib

On 14 November 2019 the European Medicines Agency (EMA) concluded that Xeljanz (tofacitinib) could increase the risk of blood clots in the lungs and in deep veins in patients who are already at high risk.  These recommendations have been formally published and are intended for EU nations utilizing tofacitinib.

Drug Interactions with Cannabinoids

Cannbinoids are widely available and used for a variety of indications, but little is known about their safety and their potential for drug interactions. The Canadian Medical Journal has published a review of drug interactions with cannabinoids, many of which are mediated by cytochrome-P450 metabolism.

Best of 2019 - Biologic Safety Guidelines from the British Society for Rheumatology

In the United Kingdom, NICE has looked to the British Society of Rheumatology (BSR) to develop evidence based guidance on the safe use of biologic DMARDs in patients with inflammatory arthritis. This guidance document on biologic safety covers baseline screening, monitoring, effect of co-morbidities, and when or under what circumstances biologic therapy should be interrupted.

Best of 2019 - Methotrexate and the Risk of Lung Disease

Rheumatology has a comprehensive overview of methotrexate (MTX) and the risk of lung injury, MTX-related pneumonitis and interstitial lung disease (RA-ILD) with rheumatoid arthritis (RA). Past reports suggest the frequence of MTX-pneumonitis to be between 0.3 and 11.6%; recent studies suggest it may be much lower.